NCT00361543View on ClinicalTrials.gov

Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
SchizophreniaSchizoaffective DisorderSchizophreniform Disorder
Interventions
DRUG

Raloxifene hydrochloride

120 mg per capsule (1 tablet daily)

OTHER

Lactose Capsules

1 tablet daily for 12 weeks

Trial Locations (1)

3004

Monash Alfred Psychiatry Research Centre, Melbourne

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

collaborator

National Health and Medical Research Council, Australia

OTHER

lead

The Alfred

OTHER

NCT00361543 - Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia | Biotech Hunter | Biotech Hunter